Barinthus Biotherapeutics
BRNS
BRNS was delisted on the 8th of September, 2026.
15 hedge funds and large institutions have $36.5M invested in Barinthus Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
24% more capital invested
Capital invested by funds: $29.5M → $36.5M (+$7.01M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 25.2% → 25.2% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
6% less funds holding
Funds holding: 16 → 15 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$39.1K |
| 2 |
Renaissance Technologies
New York
|
+$28K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16K |
| 2 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$13.5K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$309 |
BRNS Hedge Fund Activity: Q4 2023 in Review
15 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q4 2023, worth a combined $36.5M — up 24% from $29.5M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BRNS and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $39.1K. The largest seller was Morgan Stanley, cutting an estimated $16K.
- 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q4 2023, down from 16 in Q3 2023.
- Funds reported $36.5M of Barinthus Biotherapeutics stock for Q4 2023, up 24% quarter-over-quarter.
- 1 fund opened new Barinthus Biotherapeutics positions in Q4 2023 and 2 closed out, a net change of -1 holder.
- The largest Barinthus Biotherapeutics buyer in Q4 2023 was Geode Capital Management, an estimated $39.1K added.
- The largest Barinthus Biotherapeutics seller in Q4 2023 was Morgan Stanley, an estimated $16K sold.
Based on aggregated 13F filings for Q4 2023.